BEAM Beam Therapeutics Inc

Price (delayed)

$102.07

Market cap

$6.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.15

Enterprise value

$6.69B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a ...

Highlights
BEAM's equity has surged by 138% year-on-year and by 30% since the previous quarter
The EPS is up by 25% year-on-year but it has declined by 8% since the previous quarter
BEAM's quick ratio is down by 15% year-on-year but it is up by 3.9% since the previous quarter
The net income has declined by 11% since the previous quarter
The debt has grown by 4.4% from the previous quarter

Key stats

What are the main financial stats of BEAM
Market
Shares outstanding
66.35M
Market cap
$6.77B
Enterprise value
$6.69B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.64
Price to sales (P/S)
264,574.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
278,675.33
Earnings
Revenue
$24,000
EBIT
-$407.73M
EBITDA
-$402.17M
Free cash flow
-$155.22M
Per share
EPS
-$7.15
Free cash flow per share
-$2.5
Book value per share
$8.77
Revenue per share
$0
TBVPS
$14.36
Balance sheet
Total assets
$893.08M
Total liabilities
$344.53M
Debt
$142.65M
Equity
$548.55M
Working capital
$549.28M
Liquidity
Debt to equity
0.26
Current ratio
5.27
Quick ratio
5.28
Net debt/EBITDA
0.21
Margins
EBITDA margin
-1.68M%
Gross margin
100%
Net margin
-1.7M%
Operating margin
-1.41M%
Efficiency
Return on assets
-70.4%
Return on equity
-115.1%
Return on invested capital
-96.6%
Return on capital employed
-53.3%
Return on sales
-1.7M%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
-0.04%
1 week
-5.49%
1 month
0.13%
1 year
254.66%
YTD
25.02%
QTD
-20.7%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$24,000
Gross profit
$24,000
Operating income
-$337.47M
Net income
-$407.73M
Gross margin
100%
Net margin
-1.7M%
Beam Therapeutics's operating margin has decreased by 11% QoQ
Beam Therapeutics's operating income has decreased by 11% QoQ
The net income has declined by 11% since the previous quarter
The net margin has contracted by 11% from the previous quarter

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
11.64
P/S
264,574.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
278,675.33
The EPS is up by 25% year-on-year but it has declined by 8% since the previous quarter
BEAM's equity has surged by 138% year-on-year and by 30% since the previous quarter
The price to book (P/B) is 10% lower than the last 4 quarters average of 13.0
BEAM's price to sales (P/S) is 42% higher than its last 4 quarters average of 186195.4

Efficiency

How efficient is Beam Therapeutics business performance
The ROE has soared by 71% YoY and by 14% QoQ
The company's return on assets fell by 40% YoY but it rose by 17% QoQ
BEAM's ROIC is down by 26% YoY but it is up by 23% QoQ
The return on sales has declined by 11% since the previous quarter

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
The total assets is 159% more than the total liabilities
The total assets has soared by 198% YoY and by 29% from the previous quarter
Beam Therapeutics's total liabilities has increased by 27% QoQ
The debt is 74% less than the equity
BEAM's equity has surged by 138% year-on-year and by 30% since the previous quarter
The company's debt to equity has surged by 63% YoY but it fell by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.